Astal Laboratories Ltd — Important, 29-12-2025: Company Update

Astal Laboratories Limited has signed a Letter of Intent with Switzerland-based Immuna Therapeutics GmbH, securing exclusive India rights for next-generation CAR-T cell therapies, including TriCAR-T platforms. This collaboration encompasses technology transfer, localized manufacturing, clinical development, and commercialization in India. This strategic move supports Astal's expansion into high-value advanced therapies and cell/gene therapy platforms. The company estimates this partnership will generate incremental revenue of approximately ₹300 crore upon implementation, driven by rising demand for oncology treatments. It positions Astal at the forefront of next-generation immuno-oncology in India, creating a scalable platform for future cell therapy programs.